Sign in to view content

Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States

Rahul N. Khurana, MD, FASRS

Video
Published 2021

Related

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Current United States Treatment Patterns for the Treatment of Proliferative Diabetic Retinopathy in the IRIS Registry
Jeremiah Brown, MD, MS, FASRS
Annual Meeting Talks
2020
Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker For the Treatment of Diabetic Macular Edema (DME)
Victor Hugo Gonzalez, MD
Annual Meeting Talks
2024

Category: Diabetic Retinopathy

See more